ReviewJournal of frailty, sarcopenia and falls2024
What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis.
Review in Journal of frailty, sarcopenia and falls, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cardiovascular risk associated with polypharmacy in heart failure: a systematic review and meta-analysis.ESC heart failure · 2026Pooled it
- Interplay between frailty and cardiometabolic disorders: from pathophysiology to clinical implications.Cardiovascular diabetology · 2025Pooled it
- Skeletal Muscle-Cardiac Muscle Aging: Shared Mechanisms and Multimodal Interventions.JACC. Advances · 2025Review
- Impact of polypharmacy phenogroups on different heart failure phenotypes in patients with chronic heart failure: a retrospective examination of real-world cohort.Frontiers in pharmacology · 2025Article
- Improving Medication Adherence in Heart Failure Through Pharmacist-Led Patient Education: Protocol for a Mechanism-Based Study of Information, Motivation, and Behavioral Skills.Patient preference and adherence · 2025Article
- Integrating frailty interventions into existing care models: a comprehensive approach to enhancing patient outcomes in chronic disease management.Frontiers in public health · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis aimed to explore the differences in the number of prescribed medications and polypharmacy risk between patients with heart failure (HF) and frailty vs. those with HF but without frailty. Eligible studies included observational or experimental studies in patients aged ≥50 years. Thirteen studies met the criteria and were included in the final analysis. Patients with frailty and HF exhibited a higher risk of polypharmacy (OR: 1.87, 95% CI 1.72 - 2.04, I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.